Abstract
Research on the molecular basis of Alzheimers disease has elucidated pathogenic pathways from which a range of rational pharmacological interventions has emerged. The most promising strategies involve approaches to retarding, halting or preventing the formation or accumulation of beta amyloid plaques and neurofibrillary tangles. Other therapeutic approaches include those acting via excitatory amino acid receptors, limiting the oxidative stress and inflammatory response associated with dementia, molecules with nerve growth factor like activity. In the present article these and the other recent advances in the neurobiology and pharmacotherapy of AD will be reviewed.
Keywords: Non-Cholinergic Pharmacotherapy, Alzheimers Disease, neurofibrillary tangles, ampakines, acetylcholinesterase (AChE), Tau Hyperphosphorylation, calmoduline kinase
Mini-Reviews in Medicinal Chemistry
Title: Non-Cholinergic Pharmacotherapy Approaches to the Future Treatment of Alzheimers Disease
Volume: 2 Issue: 1
Author(s): Ana Castro, Santiago Conde, M. Isabel Rodriguez-Franco and Ana Martinez
Affiliation:
Keywords: Non-Cholinergic Pharmacotherapy, Alzheimers Disease, neurofibrillary tangles, ampakines, acetylcholinesterase (AChE), Tau Hyperphosphorylation, calmoduline kinase
Abstract: Research on the molecular basis of Alzheimers disease has elucidated pathogenic pathways from which a range of rational pharmacological interventions has emerged. The most promising strategies involve approaches to retarding, halting or preventing the formation or accumulation of beta amyloid plaques and neurofibrillary tangles. Other therapeutic approaches include those acting via excitatory amino acid receptors, limiting the oxidative stress and inflammatory response associated with dementia, molecules with nerve growth factor like activity. In the present article these and the other recent advances in the neurobiology and pharmacotherapy of AD will be reviewed.
Export Options
About this article
Cite this article as:
Castro Ana, Conde Santiago, Rodriguez-Franco Isabel M. and Martinez Ana, Non-Cholinergic Pharmacotherapy Approaches to the Future Treatment of Alzheimers Disease, Mini-Reviews in Medicinal Chemistry 2002; 2 (1) . https://dx.doi.org/10.2174/1389557023406610
DOI https://dx.doi.org/10.2174/1389557023406610 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Characterization of a Novel Polysaccharide-Iron(III) Complex and Its Anti-Anemia and Nonspecific Immune Regulating Activities
Mini-Reviews in Medicinal Chemistry Therapy Against Ischemic Injury
Current Pharmaceutical Design Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Factors of Rapid Cognitive Decline in Late Onset Alzheimer's Disease
Current Aging Science Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety Emerging Anticoagulant Therapies for Atrial Fibrillation: New Options, New Challenges
Current Medicinal Chemistry Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Neurobrucellosis: A Case Report with an Unusual Presentation
Recent Advances in Anti-Infective Drug Discovery Editorial [Hot Topic: QSAR Models for Computer-Aided Drug Design and Molecular Docking for Disorders of the Central Nervous System and Other Diseases]
Current Topics in Medicinal Chemistry C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia
Current Alzheimer Research